Isomorphic Labs Ltd, with headquarters in London and global business offices in Lausanne, Switzerland and Cambridge, US, announced funding of $2.1 billion on 12 May, said to be the second largest equity funding round for a company since the start of the biotechnology industry. The Series B round comes only a year after the company raised $600 million for its activities, the company’s first external financing since its launch in 2021.
